CClinicalTrials.gg
Status unknownNCT03822988PADAONCODERMUpdated Jan 30, 2019

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

An observational study in Advance Directives, Oncology and Skin Cancer, sponsored by Central Hospital, Nancy, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Central Hospital, Nancy, France · Observational

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The law about advance directives is evolving but, in France, few people write it.

Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic.

Seconds endpoints are :

For patients against or not planning to write it, understand their reasons

Estimate the proportion of patients requesting information and understand how they would like to receive it.

Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.

02

Conditions studied

  • Advance Directives
  • Oncology
  • Skin Cancer
  • Melanoma
  • Skin Lymphoma
  • Skin Squamous Cell Carcinoma
  • Metastatic Basal Cell Carcinoma

Keywords

  • advance directives
  • Advance care planning
  • Patient's informed
  • treatment preferences
  • skin cancer
  • dermatology
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 150 is close to the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cf beyond

Inclusion criteria

> 18 ya

With one of the diagnoses below:

  • Melanoma
  • Skin lymphoma
  • Meckel Carcinoma
  • localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma

Exclusion criteria

Exclusion Criteria:

Patients not in possession of all of its cognitive abilities Patients who can't read patients who don't speak french

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients accepting to answer to the survey

    patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey

    Other: no intervention, only complete a survey

Interventions

  • Otherno intervention, only complete a survey

    we will ask patients to answer to a survey

06

What researchers measure

Primary outcomes

  1. Writing by the patient of its advance directives

    Writing by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives.

    Time frame: when the patient complete the survey

Secondary outcomes

  1. reason for not writing advance directives

    In patients who have not written their advance directives: reason for not writing the advance directives.

    Time frame: when the patient complete the survey

  2. Patient wishing to be more informed about the adavance directives during its management and, if so, by what means.

    Time frame: when the patient complete the survey

07

Study locations

1 of 1 sites recruiting
  • CHRU Nancy-Brabois hospital
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03822988
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Jan 21, 2019
Primary completion
Jun 20, 2019 (estimated)
Completion
Jun 20, 2019 (estimated)
Last update
Jan 30, 2019

Study contacts

Anne-Claire BURSZTEJN
Contact
ac-bursztejn@chru-nancy.fr
0383157146
anne-claire bursztejn
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion